Variable | SRS and ipilimumab | SRS and nivolumab | Â |
---|---|---|---|
N = 45 | N = 35 | p | |
Sex (F/M) | 17/28 | 14/21 | 1.0 |
Age (years) | |||
 median | 54 | 56 | 0.2 |
 range | 23–78 | 26–80 |  |
KPS | Â | Â | 0.8 |
 median | 80 | 80 |  |
 60–70 | 13 | 9 |  |
 80–100 | 32 | 26 |  |
BRAF mutation | Â | Â | 0.8 |
 present | 15 | 13 |  |
 absent | 30 | 22 |  |
 undetermined |  |  |  |
Extracranial disease | Â | Â | 0.7 |
 present | 34 | 25 |  |
 absent | 11 | 10 |  |
Number of metastases | Â | 0.4 | |
 single | 8 | 9 |  |
 multiple | 37 | 26 |  |
DS-GPA | Â | Â | 0.3 |
 0–1 | 9 | 6 |  |
 1.5–2.5 | 22 | 16 |  |
 3–4 | 14 | 13 |  |
Type of SRS | Â | Â | 0.76 |
 Single-fraction SRS | 153 | 132 |  |
 Fractionated SRS | 22 | 19 |  |
Size of metastases | Â | Â | 0.8 |
  < 2 cm | 99 | 84 |  |
 2–3 cm | 46 | 38 |  |
  ≥ 3 cm | 30 | 29 |  |
Total tumor volume (cm 3 ) | Â | Â | 0.1 |
 median | 7.4 | 9.2 |  |
 range | 0.5–33.1 | 0.7–33 |  |
GTV (cm 3 ) | Â | Â | 0.6 |
 median | 1.12 | 1.2 |  |
 range | 0.05–27.9 | 0.4–31.2 |  |
PTV (cm 3 ) | Â | Â | 0.3 |
 median | 1.71 | 1.83 |  |
 range | 0.1–39.1 | 0.09–42.6 |  |
Conformity index a | Â | Â | 0.5 |
 median | 1.43 | 1.41 |  |
 range | 1.10–1.91 | 1.12–1.85 |  |